Comparison · Checked September 27, 2026
Semaglutide microdosing care compared: goals, evidence and quoted terms
Compare the public records for CoreAge Rx, AgelessRx and Noom without treating a shared marketing term as a shared clinical protocol.
Public-document editorial research · Method and limitations
Before comparing microdosing services, compare what they are trying to achieve. General healthy-aging support, moderate weight change and a bundled weight-management program are not interchangeable goals. A provider can use the same ingredient name while describing different preparations, patients and outcomes. A useful comparison makes those differences explicit instead of reducing them to a starting price.
CoreAge appears first for a disclosed commercial reason: Sema Evidence is part of its promotional publishing network. That ordering is not a clinical recommendation or a finding of superior safety. The following comparison uses official pages checked September 27, 2026, and does not draw on enrollment, personal treatment, provider response tests or purchases.
Article contents
CoreAge: a longevity description and a qualified shared offer
CoreAge's product page presents compounded semaglutide microdosing as a longevity-focused service, starting at $149 monthly. The linked offer page separately presents semaglutide at $79 and tirzepatide at $129, with a footer tying starting prices to a twelve-month prepaid plan. A reader therefore needs the actual semaglutide quote and terms, rather than assuming all three numbers describe the same purchase.
The page advertises no membership and ongoing access. Those service claims do not verify an exact-compound longevity outcome. Our CoreAge review records the remaining formulation, billing and evidence questions together, without using one answered question to excuse another.
AgelessRx: research interest is distinct from research results
The AgelessRx product record describes a compounded semaglutide program that may include glycine. Its $99 monthly starting figure applies to a four-month plan billed in full, followed by a displayed $159 monthly figure. The page also describes unlimited messaging, check-ins and a prescription assessment. The supplied formulation and actual subscription terms still belong to the individual care record.
An AgelessRx trial update, dated September 2, says enrollment has concluded but final participants must complete the protocol before analysis. That is evidence of a sponsor's stated research activity, not completed efficacy results. The AgelessRx review also distinguishes its customer survey from that planned analysis.
Noom: identify the program before interpreting its price
Noom's Microdose page currently names both compounded semaglutide and tirzepatide offerings. It describes a package with clinical care, medication if prescribed and behavioral support. That makes the specific medicine and selected program essential fields, rather than details that can be inferred from the Noom name.
The page advertises an initial $79 offer with distinct subscription and medicine-supply periods, followed by qualified renewal pricing. Its pricing directory also shows a $49 introductory figure alongside $79, so a current personal quote is not established by copying the lowest visible number. See the Noom review for the source-specific pricing and survey limitations.
The approved-product reference answers a narrower question
The Wegovy prescribing information defines approved uses and reports evidence for particular populations and formulations. It is a useful reference precisely because those boundaries are specified. It does not make every semaglutide-containing compound equivalent, or turn healthy-aging language into an approved indication.
Our study-population guide follows who was enrolled, what was compared and what was measured. A weight outcome does not establish a longevity outcome. A change observed in a high-risk group does not establish the same benefit in people outside that group. Cross-provider marketing cannot fill those gaps by referring generally to a well-studied ingredient.
The same word does not establish the same safety profile
These providers all use lower-dose language, but it should not be read as a common validated protocol. FDA's current concerns include measurement-related errors with compounded semaglutide, product-quality concerns and different salt forms. The warning is relevant to the quality of the clinical and pharmacy discussion; it is not a finding that a particular reviewed provider supplied a defective product.
Important approved-product risks still require professional attention. The label includes serious gastrointestinal effects and complications involving the pancreas, gallbladder and kidney, among other precautions. No price tier, online questionnaire or testimonial establishes that these issues are irrelevant to a particular person.
Compare who owns the follow-up, not just access to messaging
Messaging, coaching and clinical interpretation are different services. A useful service description identifies who responds to administrative questions, who makes prescribing decisions, and how progress or new symptoms reach that clinician. A program may advertise ongoing support while leaving actual response times or the division of responsibilities unstated.
The reviewed pages do not allow us to test those handoffs. They also do not establish every laboratory charge or state-specific restriction for an individual plan. Comparing offers means keeping unknowns visible rather than awarding points for promises that were not observed. The meaning of microdosing remains a separate question from whether a service has a convenient communication channel.
A useful comparison ends with bounded conclusions
CoreAge's shared offer needs to be reconciled with its semaglutide product page. AgelessRx's survey and trial announcement answer different evidence questions. Noom's program, medication and renewal terms must be identified together. These findings support document questions; they do not establish a universal best provider or tell a reader which treatment to choose.
Compounded-drug status is another independent boundary: FDA has not approved the finished compounds. Our pharmacy and salt-form guide keeps that distinction separate from legitimate questions about an individual prescription. The appropriate clinical discussion can include approved-product care and nonmedication assessment, without assuming that purchase of a microdose program is the necessary next step.
Source documents
A provider record supports a statement about its public description. Trial reports and product labels answer different questions and retain their own population, formulation and outcome limits.
- CoreAge Rx: Semaglutide Microdosing TherapyProvider product description · Checked 2026-09-27
- CoreAge Rx: shared microdose GLP-1 offer and footer termsProvider offer and billing disclosures · Checked 2026-09-27
- AgelessRx: Microdosing Semaglutide product, price and survey disclosuresProvider product and service description · Checked 2026-09-27
- AgelessRx: Microdosing GLP-1 for Longevity, trial update September 2, 2026Sponsor research announcement, not published trial results · Checked 2026-09-27
- Noom: Microdose GLP-1Rx program and offer qualificationsProvider program description · Checked 2026-09-27
- Noom: current medication programs and pricingProvider pricing and outcome footnotes · Checked 2026-09-27
- Wegovy prescribing information, revised June 2026Approved-product prescribing information · Checked 2026-09-27
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight LossCurrent regulatory safety information · Checked 2026-09-27
- FDA: Understanding the Risks of Compounded DrugsRegulatory explanation · Checked 2026-09-27